glp-1 trends Receptor Agonist Market Size GLP-1 Receptor Agonist Market Size

Within the SGLT2i cohort, 47% received empagliflozin, 27% received dapagliflozin and 25% received canagliflozin

The conversation typically sounds like this: I lost 30 pounds and I feel healthier, but I dont want sex anymore . At first glance, there doesnt seem to be a diagnosable problem: Patients labs look fine, their heart health has improved, their blood sugar is better, and their blood pressure dropped

Real-world studies have shown the safety and tolerability of GLP-1RAs in MS [41,62]

Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes

The future development and availability of biosimilars or generic formulations will be crucial for improving affordability and equitable access

In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as cornerstone therapies in the management of T2D and obesity [5,6,7]